SEP 23, 2016 02:26 PM PDT

Compound Blocks Fat Synthesis, Chokes Cancer's Fuel Supply


Earlier this week, I reported that scientists discovered how some cancers apparently switched off their sweet tooth to burn fat cells instead. Following this discovery, scientists at the Salk Institute found a drug that targets this fat-loving pathway in cancers.

Image credit:

Two of the better-known fat-loving cancer types are prostate cancer and acute myeloid leukemia. Unlike other cancers that prefer sugar over fat, the fat-loving cancers have a penchant for fat as their main source of fuel. Thus, in these cancers, conventional therapies that aim to starve the glucose pathway are ineffective.

In studying cancer’s appetite for fat, Salk Institute researchers found that when the demand is high, cancer cells actually speed up their own fat production. The feedback mechanism is akin to a self-perpetuating supply and demand chain – as the cancer feeds on more fat, it stimulates the cells to make more fat molecules.

"Cancer cells rewire their metabolism to support their rapid division,” noted Reuben Shaw, who heads the Salk team. Knowledge of this feedback pathway naturally pave the way to exploring potential targets that could block fat synthesis, and thereby starve out the cancer cells.

To find possible targets, the Salk team collaborated with Nimbus Therapeutics, a Boston-based biotech that specializes in discovering small molecule drugs. Together, they investigated a molecule known as ND-646, which is an acetyl-CoA Carboxylase (ACC) inhibitor. ACC is an enzyme that’s vital to fat production, and inhibiting this pathway should shut down fat-loving cancer cells.

Indeed, experiments in large-scale animal models showed remarkable results – the tumor shrank by nearly two-thirds as compared to the untreated tumors. Furthermore, choking the cancer’s fat supply seemed to work synergistically alongside a common anticancer drug, carboplatin. The combination of the ACC inhibitor and carboplatin suppressed 87 percent of cancer as compared to the 50 percent reduction from carboplatin alone.

"We found surprisingly well-tolerated dosing with some of these novel ACC inhibitors that have broad bioavailability and should not be far away from what would be needed to initiate clinical trials," said Robert Svensson, a Salk research associate and the study’s first author.

"This is the first time anyone has shown that this enzyme, ACC, is required for the growth of tumors and this represents compelling data validating the concept of being able to target fat synthesis as a novel anticancer approach," said Shaw. "The implications are that we have a very promising drug for clinical trials for subtypes of lung cancer as well as liver and other types of cancer. This represents a new weapon in the arsenal to fight cancer."

Additional source: Salk Institute

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at
You May Also Like
JUL 25, 2018
JUL 25, 2018
Can CT Scans Increase the Risk of Brain Cancer?
Medical imaging has gone from fuzzy X-rays that didn't show much, to real-time functional MRI scans in just a few decades. Being able to see inside the...
AUG 21, 2018
AUG 21, 2018
T cells Trapped by Brain Cancer
Brain tumors prevent T cells from escaping the bone marrow by altering levels of the S1P1 protein....
SEP 13, 2018
SEP 13, 2018
Breast tumors can stop their own metastasis
According to the American cancer society, metastatic breast cancers or stage 4 breast cancers have 5-years survival rate of 22% which is lower than at early stages. Metastatic breast cancer...
OCT 02, 2018
Health & Medicine
OCT 02, 2018
Many Patients Are Unaware of Increased Cancer Risk
Just as recently as a few decades ago, many common health screenings were not readily available. Mammography, for breast cancer detection, wasn't ...
OCT 05, 2018
OCT 05, 2018
FDA approves a new drug for an advanced type of skin cancer
As cancer is one of the most challenging diseases in our world, many efforts have been put into researching new ways for treatment to find new drugs that could help more patients worldwide. A...
NOV 15, 2018
Drug Discovery
NOV 15, 2018
Making Cancer Disappear?
Neuroblastoma is one of the most common childhood cancers and the leading cause of cancer deaths among pediatric patients younger than 5. The cancer is fre...
Loading Comments...